https://www.selleckchem.com/pr....oducts/eflornithine-
8% of the patients, respectively. In patients with planning target volume (PTV) ≥85 ml, acute grade ≥2 GU side effects were more common ( =.034). Our data demonstrated that UHRT administered with volumetric arc therapy (VMAT) can be recommended for selected patients with low-intermediate risk prostate cancer. Further prospective, multicentric, controlled trials on larger series are warranted to reach more accurate conclusions. Our data demonstrated that UHRT administered with volumetric arc therapy (VMAT) can
Like
Comment
Share
